Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TroVax versus placebo with first-line chemotherapy in metastatic colorectal cancer
2007-005639-26Phase 2Terminated
- Sponsor
- Oxford BioMedica
- Start
- Feb 2008
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in metastatic colorectal adenocarcinoma (mCRC) and colorectal adenocarcinoma comparing TroVax + chemotherapy with Placebo + chemotherapy (2 arms). Primary endpoint: Overall survival. Started Feb 2008; status: terminated.
02
Drugs
MVA-5T4
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)colorectal adenocarcinoma
Beyond the preview
Go deeper on 2007-005639-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005639-26.